VPAG payment rate for newer medicines will be 14.5% in 2026 The government has announced that the 2026 payment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) will be 14.5 per cent, down from a record 22.5 pe...

#ABPI #pharma #VPAG #VPAG1 #LifeSciences #Medicinessales #Pharmasales #StatutoryScheme #VoluntaryScheme #VPAGpaymentrate #VoluntarySchemeforBrandedMedicinesPricingandAccess #NHS #UKlifesciencecompetitiveness #NHSadoption #costeffectivemedicines #UKlifesciencesinvestment
zurl.co/5G14Z

Companies granted further extension to VPAG 2026 decision deadline The ABPI and the government have agreed to a further two-week extension to the deadline by which companies must give notice if they intend to leave the 2024 voluntary scheme for branded medicines pric...

#ABPI #pharmaceuticalindustry #pharmaindustry #UKpharmaindustry #VPAG2026 #UKgovernment #2024VPAG #voluntaryschemeforbrandedmedicinespricingaccessandgrowth #VPAG #VPAGscheme #lifesciencessector #StatutorySchemeforbrandedmedicines #StatutoryScheme #VPAG #VoluntaryScheme
zurl.co/P95JM

UK life sciences plan falls short, says ABPI ABPI is warning that the core ambition of the government's new life sciences strategy will not be realised unless it makes a real commitment to invest more in new medicines.

#ABPI #lifesciencesplan #lifesciences #lifesciencesstrategy #lifesciencessector #pharmaceuticalindustry #RandD #investmentinmanufacturing #lifesciences #innovativemedicines #NHSpatients #patientaccess #healthoutcomes #VPAG #StatutoryScheme #medicalinnovation
www.abpi.org.uk/media/news/2...

UK follows through on doubling of statutory scheme rate UK pharma firms have reacted angrily to the news that the government has doubled the statutory scheme rebate on the sales of newer drugs to the NHS.

The #UK #pharma industry has reacted angrily to the news that the #government has doubled the rate that #drugmakers must repay on the sales of newer products to the #NHS under the so-called #statutoryscheme.

UK doubles statutory payment rate on pharmaceutical sales from July The UK government has doubled the rate that pharmaceutical companies must repay on the sales of newer products to the NHS under the statutory scheme for branded medicines in the second half of 2025, t...

#ABPI #spendingreview #StatutoryScheme #VoluntaryScheme #VPAG #pharmaceuticalsales #UKgovernment #pharmaceuticalcompanies #NHS #brandedmedicines #NHSsales #healthcarebudget #healthcarespending #pharmaindustryinvestment #UK #VPAGreview #lifescienceinvestments
www.abpi.org.uk/media/news/2...